Correlation Among [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Cancer Antigen 27.29, and Circulating Tumor Cell Testing in Metastatic Breast Cancer

Saad, Ayman; Kanate, Abraham S.; Sehbai, Aasim; Marano, Gary; Hobbs, Gerry; Abraham, Jame

doi:10.3816/cbc.2008.n.042

Cited by 16 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating tumour cells (CTCs) are emerging as powerful response biomarkers for breast, colorectal and prostate cancers [ 15 ] . Correlations of CTCs with tumour measurements on computed tomography (CT) and fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans have been poor [ 16 , 17 ] . Correlations between CTCs and bony metastatic disease burden on FDG-PET have begun to emerge [ 18 ] .…”

Section: Skeletal Therapy Assessment Tools: Comparison Of Methodsmentioning

confidence: 99%

Bony metastases: assessing response to therapy with whole-body diffusion MRI

Padhani¹,

Gogbashian²

2011

Cancer Imaging

View full text Add to dashboard Cite

There are no universally accepted methods for assessing tumour response in skeletal sites with metastatic disease; response is assessed by a combination of imaging tests, serum and urine biochemical markers and symptoms assessments. Whole-body diffusion magnetic resonance imaging excels at bone marrow assessments at diagnosis and for therapy evaluations. It can potentially address unmet clinical and pharmaceutical needs for a reliable measure of tumour response. Signal intensity on high b-value images and apparent diffusion coefficient values can be related to underlying biophysical properties of skeletal metastases. Four patterns of change in response to therapy are described this review. Therapy response criteria need to be tested in prospective clinical studies that incorporate conventional measures of patient benefit.

show abstract

Section: Skeletal Therapy Assessment Tools: Comparison Of Methodsmentioning

confidence: 99%

Bony metastases: assessing response to therapy with whole-body diffusion MRI

Padhani¹,

Gogbashian²

2011

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…significant correlation among PET-CT scan, serum CA 27.29 levels, and CTC counts was found. 42 In this study, CA 27.29 and CTC counts had low sensitivity and a negative predictive value for the detection of metastatic disease seen on PET-CT scan. 42 However, clinical outcome was not evaluated in this study, and the relative ability for each test to predict therapy response was not assessed.…”

Section: Prognostic Significance Of Ctcsmentioning

confidence: 56%

Circulating and Disseminated Tumor Cells in the Management of Breast Cancer

Ross

Slodkowska

2009

Am J Clin Pathol

View full text Add to dashboard Cite

Despite the advances in early detection and treatment of cancer, patients continue to die of the disease even when they seek care at an early stage. For patients with breast cancer, it is now possible to detect circulating tumor cells (CTCs) in the bloodstream and disseminated tumor cells (DTCs) in the bone marrow by using immunocytochemical and molecular methods. CTCs and DTCs have been found to share similar genotypic and phenotypic characteristics with so-called breast cancer stem cells, a finding that could potentially explain the eventual relapse of disease in a patient previously considered to have been cured by primary therapy. In some studies, the presence of CTCs or DTCs at the time of diagnosis of breast cancer is an independent adverse prognostic variable. However, before CTC/DTC testing can achieve standard-of-care status, there must be improvement in the sensitivity, precision, and reproducibility of the detection methods.

show abstract

“…Nevertheless, these studies concluded that CTC measurement is valuable because of its speed, high specificity, and low variability and suggested continued use of imaging in patients without detectable CTCs [30, 43]. However, as noted previously, the absence of CTCs is in itself a relative positive prognostic factor that should be considered along with imaging results.…”

Section: Integration Of Ctc Measurement With Mbc Therapiesmentioning

confidence: 99%

“…The authors concluded that their data supported the clinical utility of serial CTC enumeration in conjunction with standard radiographic imaging to monitor disease status and treatment efficacy. CTC enumeration has also been compared to imaging with fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) [30, 43]. Serial radiographic imaging and FDG-PET/CT were shown to correlate with CTC levels, with CTC counts having the advantages of higher precision, better responsiveness to disease state changes, and predictive capability.…”

Section: Integration Of Ctc Measurement With Mbc Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy

Alemar

Schuur

2013

Journal of Oncology

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) were discovered nearly 150 years ago but have only recently been recognized as a feature of most solid tumors due to their extremely low concentration in the peripheral circulation. Several technologies have been developed to isolate and analyze CTCs, which can now be routinely accessed for clinical information. The most mature of these (the CELLSEARCH system) uses immunomagnetic selection of epithelial cell adhesion molecule to isolate CTCs for analysis. Studies using this system have demonstrated that categorization of patients into high and low CTC groups using a validated decision point is prognostic in patients with metastatic breast, colorectal, or prostate cancer. Initial attempts to use CTC counts to guide therapeutic decisions appeared to yield positive results and key concepts in clinical application of CTC information, including the CTC cutoff, predictive value in disease subtypes, and comparison to current evaluation methods, have been demonstrated. Clinical studies of the impact of CTC counts in routine clinical practice are ongoing; however, recent published evidence on the clinical use of CTCs in metastatic breast cancer continues to support these concepts, and experience in the community oncology setting also suggests that CTC enumeration can be useful for therapy management.

show abstract

Correlation Among [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Cancer Antigen 27.29, and Circulating Tumor Cell Testing in Metastatic Breast Cancer

Cited by 16 publications

References 13 publications

Bony metastases: assessing response to therapy with whole-body diffusion MRI

Bony metastases: assessing response to therapy with whole-body diffusion MRI

Circulating and Disseminated Tumor Cells in the Management of Breast Cancer

Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy

Contact Info

Product

Resources

About